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Objective   To investigate the association of running participation and the dose of running with 
the risk of all-cause, cardiovascular, and cancer mortality. 
Design   Systematic review and meta-analysis. 
Data sources   Journal articles, conference papers, and doctoral theses indexed in Academic 
Search Ultimate, CINAHL, Health Source: Nursing/Academic Edition, MasterFILE Complete, 
Networked Digital Library of Theses and Dissertations, Open Access Theses and Dissertations, 
PsycINFO, PubMed/MEDLINE, Scopus, SPORTDiscus, and Web of Science. 
Eligibility criteria for selecting studies   Prospective cohort studies on the association between 
running or jogging participation and the risk of all-cause, cardiovascular, and/or cancer mortality 
in a non-clinical population of adults were considered eligible for inclusion. 
Results   Fourteen studies from six prospective cohorts with a pooled sample of 232,149 
participants were included. In total, 25,951 deaths were recorded during 5.5–35 year follow-ups. 
Our meta-analysis showed that running participation is associated with 27%, 30%, and 23% lower 
risk of all-cause (pooled adjusted hazard ratio [HR] = 0.73; 95% confidence interval [CI]: 0.68, 
0.79), cardiovascular (HR = 0.70; 95% CI: 0.49, 0.98), and cancer (HR = 0.77; 95% CI: 0.68, 0.87) 
mortality, respectively, compared to no running. A meta-regression analysis revealed no 
significant dose-response trends for weekly frequency, weekly duration, pace, and the total volume 
of running. 
Conclusion   Increased rates of participation in running, regardless of its dose, would likely lead 
to substantial improvements in population health and longevity. Any amount of running, even just 
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once per week, is better than no running, whilst higher doses of running may not necessarily be 
associated with greater mortality benefits.  
 
What is already known 
- It is unclear how running participation and the dose of running are associated with 
the risk of all-cause, cardiovascular, and cancer mortality 
What are the new findings 
- Running participation is associated with 27%, 30%, and 23% reduced risk of all-
cause, cardiovascular, and cancer mortality, respectively 
- Significant reductions in mortality risk can be expected for any dose of running, 
even just once per week or 50 minutes a week 












Global and national public health authorities recommend adults to engage in 150 minutes of 
moderate- to vigorous-intensity physical activity (MVPA) a week.[1-5] The epidemiological 
literature strongly supports the beneficial associations of total amount of MVPA with health 
outcomes.[6-10] Several systematic reviews and meta-analyses have summarized the evidence on 
the association between MVPA and the risk of disease-specific and all-cause mortality.[11-16] For 
example, a meta-analysis found that insufficient MVPA (defined as not meeting the current WHO 
guidelines for MVPA[1]) is associated with a 28% higher risk of all-cause mortality compared to 
sufficient MVPA.[15] Considering the high levels of physical inactivity globally, Lee and 
colleagues estimated that more than 5 million premature deaths a year would be prevented if 
insufficiently physically active people were to become sufficiently active.[15] Beyond the total 
amount of MVPA, there has been considerable interest in how different types of physical activity 
(e.g. walking, cycling, running, swimming) affect health and risk of premature mortality.[17-24] 
In other words, for any given amount of MVPA, does it matter for health what types of physical 
activity people do?  
 
Running is among the most popular types of physical activity. For example, it has been estimated 
that each month around 3.7 million (8.5%) English adults participate in running as a sport or 
recreational activity.[25] Other countries, such as Australia[26] and the US,[27] have comparably 
high participation rates. The 2017 Physical Activity Council’s survey ranked running in the top 
ten preferred activities that 25-44-year-old US adults who did not participate in sports or exercise 
wished to engage in.[28] Given its popularity, running as a sport and recreational activity has great 
potential for improving population health. The Royal College of General Practitioners (RCGP) has 
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acknowledged this potential by partnering with the parkrun UK initiative, to promote the uptake 
of running and walking among general practitioners and their patients.[29] 
 
In a systematic review of observational and intervention studies published in 2015, Oja et al.[17] 
concluded that the evidence on health benefits is scarce for participation in all sports except for 
running and football. The authors concluded that there is: [i] moderate evidence for the 
associations between running and improved aerobic fitness, cardiovascular function, and running 
performance; [ii] limited evidence for the associations of running with improvements in metabolic 
fitness, adiposity status, and postural balance; and [iii] inconclusive evidence for the associations 
of running with cardiac adaptation, muscular strength, and disease-specific and all-cause 
mortality.[17] Oja et al.[17] identified only one study on running participation and the risk of 
mortality. A subsequent, comprehensive narrative review summarised the evidence on the 
association of running and a range of health outcomes, including major cardiometabolic outcomes, 
bone and respiratory health, disability, as well as disease-specific and all-cause mortality.[22] The 
strength of the association between running participation and the risk of all-cause and disease-
specific mortality varied across different studies.[22] To date, no meta-analysis has synthesised 
evidence on the association between running participation and the risk of mortality. 
 
From public health and exercise prescription perspectives, identifying the optimal doses of running 
for improved health outcomes is crucial. The “dose” of running is usually defined by its frequency 
(e.g. two times a week), overall duration in a given period (e.g. 40 minutes/week), pace (e.g. 10 
km/h), and the total volume (e.g. expressed as the product of the overall weekly duration of running 
and the metabolic equivalent [MET] of running at a given pace; 800 MET-minutes/week).[30, 31] 
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It is plausible that higher running doses would lead to better health outcomes, such as improved 
physical and metabolic fitness, that are on the causal pathway between physical activity and lower 
mortality risk.[32] Contrary to this assumption, in 2015, Schnohr et al.[31] suggested there may 
be a U-shaped relationship between the dose of running and the risk of all-cause mortality. 
Compared to “sedentary” nonrunners, those who ran less than 2.5 hours a week, those who ran 
less than four times a week, and those who ran in a slow or average pace had significantly lower 
risks of all-cause mortality.[31] No statistically significant adjusted hazard ratios (HRs) were 
found for those who ran 2.5 or more hours a week, those who ran four or more times a week, and 
those who ran in a fast pace.[31] The U-shaped relationship may be explained by possible 
pathological changes in cardiovascular tissues induced by extreme doses of endurance sports over 
a long term; for example, by the development of patchy myocardial fibrosis that can trigger heart 
arrhythmias.[33] However, a relatively small number of participants in the Schnohr et al.[31] study 
were classified as “strenuous” runners and only a few death cases were registered in this group, 
limiting the statistical power of the analysis. The finding has sparked a lot of discussion among 
researchers.[22, 30, 34-40] To date, the available evidence on the dose-response relationship 
between running and the risk of mortality has not been synthesised in a meta-analysis. 
 
The aim of this systematic review and meta-analysis was, therefore, to synthesise available 
evidence on the association of running participation and the dose of running with the risk of all-





This review was conducted according to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines.[41] The review protocol has been registered in the 
International Prospective Register of Systematic Reviews – PROSPERO (registration id: 
CRD42016049965). 
 
Literature search  
We systematically searched PubMed/MEDLINE, Scopus, EBSCOHost (including Academic 
Search Ultimate, CINAHL, Health Source: Nursing/Academic Edition, MasterFILE Complete, 
PsycINFO, and SPORTDiscus), and Web of Science for journal articles and conference papers 
published from the database inception to February 2019. Additionally, we searched for doctoral 
and master theses through Networked Digital Library of Theses and Dissertations (NDLTD) and 
Open Access Theses and Dissertations (OATD) databases. The searches were performed by 
combining the keywords “running”, “jogging”, “runner*”, and “jogger*” with the keywords 
“mortalit*”, “death*”, and “fatal*”. The search syntax can be found in online supplementary file 
1. The reference lists of all included studies were checked to identify any titles that were not 
considered for inclusion in the primary literature search. The discrepancies of the literature search 
from the registered protocol are specified in online supplementary file 2. 
 
Study selection 
Two authors (ZP, NS) independently assessed the identified publications for relevance. When 
needed, the authors resolved disagreement by consulting and discussing with a third author (JG). 
Studies meeting the following criteria were included in the present review: 1) a prospective cohort 
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study; 2) adult sample (≥18 years of age); 3) non-clinical study population (i.e. a population not 
defined by the presence of a disease or a health condition); and 4) reported the association between 




Using a predefined form, two authors (ZP and NS) independently extracted the following data 
from the included studies: 1) study date and location; 2) type of sample, sample size, and gender 
distribution; 3) age of study participants (range and mean ± standard deviation); 4) duration of 
follow-up; 5) number of person-years; 6) number of runners and nonrunners in the sample; 7) 
number of mortality events in the total sample, among non-runners, and among runners; 8) the 
method of running assessment; 9) the mode of outcome assessment; 10) adjustments for potential 
confounding variables; 11) type of statistical analyses; and 12) key results on the association 
between running participation and the dose of running with the risk of all-cause, cardiovascular, 
and cancer mortality (online supplementary tables 1 and 2). Discrepancies in the extracted data 
were resolved by consulting and discussing with a third author (JG). Where needed, we also 
contacted authors of included studies to provide unpublished data. 
 
Assessment of study and evidence quality 
Two authors (NL and SJHB) independently assessed the quality of included studies using the 
Newcastle-Ottawa Quality Assessment Scale (NOS) for cohort studies.[42] Details about the scale 
items and the scoring system can be found elsewhere.[42] The appraised studies were classified 
based on their overall score on the NOS scale as being of “poor quality” (0-3 points), “fair quality” 
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(4-6 points), or “good quality” (7-9) points. Discrepancies in the results of the two independent 
quality assessments were resolved by a third author (JG).  
 
Assessment of adjustments for confounding 
The appropriateness of adjustments for confounding in each study was assessed against directed 
acyclic graphs (DAG).[43] A possible representation of the directions of relationships is presented 
in figure 1. According to this DAG, for estimating the effect of running (through subsequent health 
status) on mortality risk, it would be necessary to adjust for sociodemographic factors, unhealthy 
lifestyle (e.g. smoking, alcohol intake, dietary habits), adiposity, health status, and physical activity 
other than running. 
 
Figure 1  Directed acyclic graph (DAG) for the relationship between running participation and 
mortality risk. Green circle = exposure; blue circle = outcome; light grey circle = unobserved 




If multiple analyses were conducted on the same cohort and published separately, our meta-
analyses included estimates from the publication with the longest follow-up. We pooled individual 
HRs from the models that satisfied (or were the closest to satisfying) the adjustment requirements 
specified according to the DAG in figure 1; which is likely to provide conservative estimates. We 
did this using a random-effects meta-analysis, separately for all-cause, cardiovascular, and cancer 
mortality. We carried out the following additional analyses for all-cause mortality: 
• (a) a subgroup analysis by gender;  
• (b) a sensitivity analysis where we only included the studies classified as “good quality”; 
• (c) a sensitivity analysis where we included the most recent study from the Copenhagen 
City Heart Study cohort[44] instead of the one with the longest follow-up and the largest 
sample size.[45]; 
• (d) a sensitivity analysis where we included HRs from an alternative model in the Lee et 
al. [46] study (see description of Model 2 in online supplementary table 1);  
• (e) a sensitivity analysis where we additionally replaced HRs from the Oja et al.[18] study 
with the estimates from the Stamatakis et al.[19] study, that is, a subsequent analysis of 
the same data with further adjustments for social class and household income.  
We also carried out the same sensitivity analyses as (d) and (e) above for CVD mortality. We 
assessed statistical heterogeneity of the HRs using the I2 statistic, where I2 values of 0%-40%, 30%-
60%, 50%-90%, and 75%-100% were considered to represent low, moderate, substantial, and high 
heterogeneity, respectively.[47] We could not assess publication bias by using Egger’s asymmetry 




The dose-response relationships from individual studies were pooled using a random-effects meta-
regression analysis with Restricted Maximum Likelihood (REML) estimation. Prior to the meta-
regression analysis of dose-response relationships, we harmonised the doses reported in individual 
studies. The doses that did not exactly match were harmonised according to the closest midpoint. 
This was done by one author (ZP) and checked for consistency and accuracy by another author 
(ST). If multiple studies from the same cohort presented data on dose-response relationships, we 
included in the meta-regression analysis the one that used the most detailed classification of dose. 
The categories of dose can be found in online supplementary table 2. We considered linear, 
quadratic, log-linear, and log-quadratic models when examining the dose-response curves. The 
model selection was based on the Akaike Information Criterion (AIC). The model with the smallest 
AIC statistic was considered to have the best balance between the simplicity and the goodness of 
fit. All analyses were conducted in R (R Foundation for Statistical Computing, Vienna, Austria), 
using the ‘metafor’ package.[49] 
 
RESULTS 
Search and study selection results 
The primary search resulted in a total of 19,315 references (figure 2). After removing 4,912 
duplicates, we assessed 14,403 references against the inclusion criteria. Out of these, 13 
publications[18, 30, 31, 44-46, 50-56] met all the inclusion criteria. Additionally, one eligible 
publication[19] was identified in the secondary search, from the reference lists of the included 
papers. This resulted in a total of 14 included publications, reporting results from the following 
cohort studies: the Aerobics Center Longitudinal Study (USA);[30, 46, 50] the Copenhagen City 
Heart Study (Denmark);[31, 44, 45, 56] the Health Survey for England and the Scottish Health 
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Survey (UK; hereinafter referred to as a single study, as their data were pooled);[18, 19] the 
National Health and Nutrition Examination Survey (USA);[54] the Shanghai Men’s Health Study 
(China);[51] and a cohort of runners from the 50+ Runners Association with controls from the 
Stanford University Lipid Research Clinics Prevalence Study (USA).[52, 53, 55] 
 




The Wang et al.[51] study included only men, whilst the other studies included both sexes (online 
supplementary table 1). Four study samples were population-representative[18, 45, 51, 54], whilst 
the remaining two studies used convenience samples.[46, 55] The pooled sample size from the 
studies included in this review is 232,149, with individual study samples ranging from 961 to 
80,306 participants. In all included studies, the data on running participation were collected using 
self-reports and the participants classified as runners (i.e. the exposure group) comprised around 
10% of the pooled sample. The mortality data in all studies were obtained from national death 
registers, with the follow-up across individual studies ranging from 5.5 to 35 years. In total, 25,951 
deaths were recorded in the study samples during follow-up. 
 
Adjusted HRs suitable for the meta-analysis of the association between running participation and 
the risk of all-cause mortality were available from all cohorts except the National Health and 
Nutrition Examination Survey[54] (online supplementary table 1). Three studies reported adjusted 
HRs suitable for inclusion in the meta-analysis of the association between running participation 
and the risk of cardiovascular mortality.[18, 46, 51] Adjusted HRs suitable for the meta-analysis 
of the association between running participation and the risk of cancer mortality were available in 
three studies[30, 45, 51] and obtained upon request from the authors of one additional study.[18] 
 
Findings on the relationship between the dose of running and the risk of all-cause mortality were 
available in five publications from three cohort studies (online supplementary table 2).[18, 30, 31, 
45, 46] Analyses of dose-response relationships using the data from the Aerobics Center 
Longitudinal Study were conducted by Lee et al.[30, 46]. The Lee et al.[30] study includes a more 
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detailed classification of weekly duration, weekly frequency, and total volume of running. 
However, unlike in the Lee et al.[46] study, Lee et al.[30] did not analyse the relationship between 
running pace and mortality risk. Analyses of dose-response relationships from the Copenhagen 
City Heart Study data were conducted by Schnohr et al.[31, 45]. Schnohr et al.[31] study presented 
a more detailed analysis of the dose-response relationships. Furthermore, findings on the 
relationships between the dose of running and the risk of cardiovascular mortality were available 
in three publications from two cohort studies.[18, 30, 46] The relationship between the dose of 
running and the risk of cancer mortality was analysed in one study.[50] 
 
The studies by Fries et al.,[52] Wang et al.,[53] and Schnohr et al.[56] were conducted using data 
from shorter follow-ups and with less death cases than subsequent, more recent studies from the 
respective cohorts.[45, 55] Furthermore, Schnohr et al.[44] was the most recent publication from 
the Copenhagen City Heart Study reporting the association between running and mortality. 
However, they included only participants of the third examination (1991-1994), which resulted in 
a shorter follow-up, a smaller sample size, and fewer number of deaths, when compared to a 
previous study from the same cohort.[45] Furthermore, in Stamatakis et al. study,[19] a large 
amount of missing data for the two additional variables included in the model (added on top of the 
original set of variables used in the Oja et al.[18] study) resulted in a significantly reduced sample 
size compared to the sample size in the original study.[18] 
 
Methodological quality of the included studies 
The included studies were given overall scores ranging from four to nine points out of the 
maximum of nine points on the NOS scale (online supplementary table 3). Based on the overall 
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scores, one study[55] was classified as being of “fair quality”, whilst all other studies were 
classified as being of “good quality”. 
 
Adjustments for confounding 
In regard to adjustments for confounding, models in the Oja et al.,[18] Stamatakis et al.,[19] 
Schnohr et al.,[45] and Wang et al.[51] studies, satisfied all the requirements for causal effect 
identification specified in figure 1. The other studies did not adjust for all the variables. For 
example, Chakravarty et al.[55] presented HRs adjusted for age, gender, and initial disability. Lee 
et al.[46] calculated HRs adjusted for age, sex, examination year, smoking status, alcohol 
consumption, other physical activities except running in one model and HRs adjusted for age, sex, 
examination year, smoking status, overweight/obesity, parental CVD, abnormal 
electrocardiogram, hypertension, diabetes, and hypercholesterolemia in another model. 
 
Results of meta-analyses 
Running participation and the risk of all-cause mortality 
The random-effects meta-analysis of adjusted HRs showed running participation was associated 
with a reduction in the risk of all-cause mortality of 27% over the follow-up periods (figure 3; HR 
= 0.73; 95% confidence interval [CI]: 0.68, 0.79; p < 0.001). No significant heterogeneity in the 
effect sizes was found across the five studies (I2 = 8.54%). Similar results were obtained in all four 
sensitivity analyses (online supplementary figures 1-4). 
 
A subgroup meta-analysis by sex showed similar results as the main analysis (online 
supplementary figures 5 and 6). The analysis for females and the analysis for males included HRs 
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available from two studies[45, 46] and three studies[45, 46, 51], respectively. The random-effects 
meta-analysis of adjusted HRs showed running participation was associated with a reduction in 
the risk of all-cause mortality of 34% for females (HR = 0.66; 95% CI: 0.52, 0.83; p < 0.001) and 
27% for males (HR = 0.73; 95% CI: 0.67, 0.79; p < 0.001). No significant heterogeneity was found 
between the effect sizes from different studies (I2 < 0.001% for both analyses). 
 
Figure 3  Running participation and all-cause mortality risk: a meta-analysis of hazard ratios. HR, 
adjusted hazard ratio (the list of variables that were adjusted for in each study is available in online 
supplementary table 1); 95% CI, 95% confidence interval for HR; f, female subsample; m, male 






Running participation and the risk of cardiovascular mortality 
The random-effects meta-analysis of adjusted HRs showed running participation was associated 
with a reduction in the risk of cardiovascular mortality of 30% over the follow-up periods (figure 
4; HR = 0.70; 95% CI: 0.49, 0.98; p = 0.040). Substantial heterogeneity in the effect sizes was 
found across the three studies (I2 = 63.44%). Similar pooled HRs were obtained in both sensitivity 
analyses (online supplementary figures 7 and 8).  
 
Figure 4  Running participation and cardiovascular mortality risk: a meta-analysis of hazard ratios. 
HR, adjusted hazard ratio (the list of variables that were adjusted for in each study is available in 
online supplementary table 1); 95% CI, 95% confidence interval for HR; RE Model, pooled effect 






Running participation and the risk of cancer mortality 
The random-effects meta-analysis of adjusted HRs showed running participation was associated 
with a reduction in the risk of cancer mortality of 23% over the follow-up periods (figure 5; HR = 
0.77; 95% CI: 0.68, 0.87; p < 0.001). There was no significant heterogeneity between the effect 
sizes from the four individual studies (I2 < 0.001%). 
 
Figure 5  Running participation and cancer mortality risk: a meta-analysis of hazard ratios. HR, 
adjusted hazard ratio (the list of variables that were adjusted for in each study is available in online 
supplementary table 1); 95% CI, 95% confidence interval for HR; f, female subsample; m, male 
subsample; RE Model, pooled effect size from a random-effects meta-analysis model; the meta-






Dose of running and the risk of mortality 
We conducted meta-regression analyses only for the dose-response relationship between running 
and all-cause mortality (figure 6), because insufficient data from individual studies were available 
for cardiovascular and cancer mortality as outcome variables. In all four meta-regression analyses, 
the linear model had the lowest AIC value (12.36, 2.76, 7.41, and 13.95 in the analysis for 
frequency, duration, pace, and volume, respectively) compared to the other models. This suggested 
that the most parsimonious representation of the dose-response data was provided by a linear fit. 
However, no significant trends for dose response were found (p > 0.05 for all). There was moderate 
heterogeneity between the studies included in the meta-regression analyses for frequency, 
duration, and pace of running. The I2 values were 47.62%, 32.88%, and 41.25%, respectively. We 
found substantial heterogeneity between the studies included in the meta-regression for the total 
volume of running (I2 = 62.57%). The meta-regression coefficients for the linear trend are 
presented in online supplementary table 4. They can be used to calculate the estimated pooled HR 
from the three analysed cohorts for a given dose of running. For example, the estimated pooled 
HR for the total volume of running of 675 MET-minutes/week (i.e., roughly equivalent to the 




Figure 6  Dose of running and all-cause mortality risk: a meta-regression of hazard ratios. Blue 
circle, an adjusted hazard ratio (HR) from Lee et al. [46] for “pace” and Lee et al. [30] for 
“frequency”,“duration” and “volume”; orange circle, HR from Oja et al. [18] ; green circle, HR 
from Schnohr et al. [31]; The size of a circle is proportional to the precision of each study’s 





This systematic review synthesised results of fourteen studies from six prospective cohorts with a 
pooled sample of more than 230 thousand participants. The main finding is that running 
participation is associated with 27%, 30%, and 23% reduced risk of all-cause, cardiovascular, and 
cancer mortality, respectively. A meta-regression analysis combining results from three cohort 
studies revealed no significant dose-response trends. Even the smallest doses of running that were 
examined in the available studies (i.e. ≤1 time a week, <50 minutes a week, <6 mph, and <500 
MET-minutes/week) were found to confer significant all-cause mortality benefits. We found no 
evidence that mortality benefits increase with higher amounts of running. 
 
Comparison with other studies 
The systematic review by Oja and colleagues[17] included only one study on running participation 
and mortality risk. Two articles presented findings of more recent literature searches on health 
outcomes of running,[22, 57] but they were both narrative reviews and did not conduct meta-
analyses to quantitatively estimate the pooled associations of running with health outcomes. To 
our knowledge, the current study is the first meta-analysis of the association between running 
participation and the risk of mortality. 
 
A meta-analysis by Kelly and colleagues[21] found that 675 MET-minutes/week of walking and 
cycling (i.e., roughly equivalent to the current WHO MVPA recommendations[1]) is associated 
with a reduction in the risk of all-cause mortality by 11% (95% CI: 4%, 17%) and 10% (95% CI: 
6%, 13%), respectively. In the sample of three cohort studies included in our meta-regression 
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analysis, we found that the same weekly volume of running conferred significantly greater 
mortality benefit (32%, 95% CI: 22%, 49%). However, the difference between mortality benefits 
for running, walking, and cycling seems to disappear at moderate and high total volumes of these 
activities. The ratios of metabolic rates of walking, cycling, and running to the resting metabolic 
rate (i.e. METs) vary significantly between and within individuals, depending greatly on the pace 
of activity.[58] We speculate that during short exercise/activity sessions, the intensity (expressed 
in METs) is on average higher for running than for walking and cycling. This would explain the 
observed difference between mortality benefits,[21] given that greater reductions in mortality risk 
are associated with participation in vigorous-intensity sports and exercise when compared to 
activities of lower intensities.[14] This finding warrants further research that would make direct 
comparisons between the associations of running, walking, and cycling with the risk of mortality 
in the same study sample(s). 
 
A recent meta-analysis summarised the results of 35 running interventions (randomised controlled 
trials) among a total sample of more than 2,000 otherwise physically inactive adults.[59] Running 
roughly 3-4 times and 2-3 hours a week at the intensity of 60%-90% of the maximum heart rate 
for one year reduced body fat on average by 2.7%, resting heart rate by 6.7 beats per minute, and 
triglycerides by 16.9 mg/dL, whilst increasing the average maximal oxygen uptake (VO2max) by 
7.1 mL/min·kg and high-density lipoprotein (HDL) cholesterol by 3.3 mg/dL. These findings 
likely explain some of the underlying causal pathways linking running participation and lower 
mortality risk. In support of this notion, Lee et al.[46] found no association between running and 
mortality after adjusting for cardiorespiratory fitness. Although all studies in this review excluded 
participants with a history of severe illness at the baseline and/or adjusted their analysis for health 
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status, the possibility of reverse causation between running participation and health cannot be ruled 
out. In other words, the association between running and mortality may partially be explained by 
assuming that sick participants (who are more likely to die) were less likely to engage in running. 
 
 
Implications for clinicians and policymakers 
Some clinicians and public health stakeholders may have been discouraged from promoting 
running as a part of “lifestyle medicine” among their patients and communities, because vigorous 
exertion has been linked with sudden cardiac death.[60]. Our results provide meta-analytic 
evidence that, in the general population, the mortality benefit of running outweighs the risk. 
Previous studies suggested that this also holds true for some clinical populations.[22, 57] However, 
running might not be a suitable activity for all clinical populations, and a clinician may need to 
make an informed decision on whether or not to prescribe it on a case-by-case basis. Furthermore, 
participation in running is also associated with an increased injury risk, and the risk increases with 
increasing daily duration of the activity.[61] In cases when there is an increased risk of running-
related overuse injuries,[62] clinicians may consider recommending walking or a lower dose of 
running. Our findings support such a recommendation by highlighting likely mortality benefits of 
low running doses. 
 
The World Health Organization (WHO) guidelines and national physical activity 
recommendations in many countries (including the UK) suggest that adults should engage in at 
least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity physical activity a 
week.[1, 3] Seventy-five minutes per week of physical activity at the lower threshold for vigorous-
25 
 
intensity (i.e. 6 METs) equals to 450 MET-minutes/week. Dose-response analyses from both the 
Aerobics Center Longitudinal Study[30] and the Health Survey for England/Scottish Health 
Survey[18] showed that even <506 MET-minutes/week of running are associated with a significant 
mortality benefit. These findings support the physical activity recommendation. However, >80% 
of runners seem to run at the pace faster than 6 mph,[46] which is associated with an energy cost 
of >9.8 METs.[58] This means that many runners could achieve mortality benefits with less than 
~50 minutes a week, that is, in 25 minutes less than the recommended minimum amount of 
vigorous-intensity physical activity. This may be encouraging for people who struggle to find the 
time to exercise, given that a perceived lack of time has been consistently identified as a key barrier 
to physical activity participation.[63] Furthermore, the national physical activity recommendations 
in many countries suggest that more physical activity may confer additional health benefits, often 
referring to ≥300 minutes of moderate-intensity or ≥150 minutes of vigorous-intensity physical 
activity.[3] The results of our dose-response analysis do not support this recommendation in terms 
of running behaviour and mortality risk. 
 
Strengths and limitations of the review and included studies 
The key strength of this study was the rigorous methodological protocol, following PRISMA 
guidelines for systematic reviews.[41] We searched for eligible publications in a large number of 
bibliographic databases using broad search terms, which ensured that relevant studies were 
unlikely to be missed. Additionally, we contacted authors of three included studies[18, 45, 55] in 
an attempt to obtain unpublished data, and we obtained additional data from one study,[18] which 
has improved the comprehensiveness of our analyses. A limitation of this review is that, due to a 
small number of included studies, we could not assess publication bias. Moreover, one of the 
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included studies[54] reported a non-significant association between running participation and the 
risk of all-cause mortality, but it did not present results suitable for our meta-analysis. It might, 
therefore, be that the pooled HR for the association between running and mortality is somewhat 
overestimated. 
 
All included studies were of good methodological quality, except for one study that was of fair 
quality. Despite their high scores on the methodological quality checklist, the studies had some 
limitations. First, although the analyses in all studies were adjusted for a range of variables, their 
results may have been affected by residual confounding. For example, one study[55] did not adjust 
for physical activities other than running. Higher physical activity levels are associated with a 
lower risk of mortality.[15] Not adjusting for this variable may have led to misestimation of the 
effects of running, that is, an overestimation, if physical activity other than running was higher 
among runners than among nonrunners, or an underestimation, if physical activity other than 
running was higher among nonrunners than among runners. It is worth noting that Chakravarty et 
al.[55] considered aerobic exercise as a covariate, but they decided not to include it in the final 
model, because it did not significantly alter the results. Only four studies[18, 19, 45, 51] satisfied 
all the requirements for causal effect identification specified in figure 1. However, it is possible 
that some causal relationships are in the opposite direction than those assumed in the DAG in 
figure 1. According to a less ‘conservative’ DAG (online supplementary figure 9), it would only 
be necessary to adjust for sociodemographic factors, unhealthy lifestyle, and health status. 
According to this ‘less conservative’ DAG, further adjustments for either adiposity or physical 
activity other than running would lead to over-adjustment. Second, the criteria for excluding 
participants in the included studies were usually limited to a history of cardiovascular disease or 
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cancer. Other diseases and debilitating conditions could prevent people from running whilst at the 
same time increasing their risk of dying prematurely. Third, results of some individual studies may 
have been affected by selection bias. For example, in one study,[55] the exposure group and the 
controls were not drawn from the same source, which was reflected in significant baseline 
differences between the groups. However, the exclusion of this study from the meta-analysis for 
all-cause mortality resulted in no significant change in the pooled HR. In the dose-response 
analysis from another study,[31] the reference group was defined as “sedentary nonrunners”. This 
might have led to an overestimation of mortality benefits of running, as it is likely that lower 
mortality rates in the exposure group were partially attributable to physical activity other than 
running. Due to the low number of studies that reported dose-response relationships, we could not 
conduct a sensitivity analysis by excluding this study. Fourth, although it generally seems that 
running is a relatively stable habit,[45] individuals may change their running behaviour over the 
years of follow-up. Only two included studies examined the association between persistence in 
running behaviour over time and mortality.[46, 56] Fifth, although distance is a potentially useful 
measure of running dose, it was assessed in one cohort study only.[46] Sixth, the included studies 
used self-reports to collect data on running participation. Potential issues with validity and 
reliability of such self-reported data[64] may have resulted in attenuated associations between 
running participation and mortality. It is reasonable to assume that the shape of the observed dose-
response curves could have been affected by such limitations of the measurement. Besides, the 
questions about running varied across the cohorts, which may have reduced the between-study 
comparability of exposure data. Seventh, in the meta-analyses, we could not account for the fact 
that the weekly frequency, weekly duration, and pace of running were likely co-dependent. A 
future meta-analysis of individual-level data would be needed to address this issue.[65] Finally, 
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the number of participants in the included studies and, consequently, the precision of estimates 
tended to be lower for higher doses of running. Although our meta-regression accounted for the 
varying precision of estimates across doses, a larger number of participants with high doses of 
running would improve the pooled estimates. 
 
Conclusions and recommendations for future research 
Running participation is associated with a significantly lower risk of all-cause, cardiovascular, and 
cancer mortality, compared to no running. Any amount of running, even just once per week, is 
better than no running, whilst higher doses of running may not necessarily be associated with 
greater mortality benefits. Increased rates of participation in running, regardless of its dose, would 
likely lead to substantial improvements in population health and longevity. 
 
More studies are needed to examine how sustained running behaviour over time, compared to 
sporadic participation in running, is associated with mortality risk. Future studies should also 
consider assessing running habits using activity trackers, as these devices have the potential to 
provide more detailed and accurate insights into running behaviour. 
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Supplementary file 1   Search syntax 
 
EBSCOHost (including Academic Search Ultimate, CINAHL, Health Source: 
Nursing/Academic Edition, MasterFILE Complete, PsycINFO, and SPORTDiscus) 
(running OR jogging OR runner* OR jogger*) AND (mortalit* OR death* OR fatal*) 
 
Networked Digital Library of Theses and Dissertations (NDLTD) 
(running OR jogging OR runner* OR jogger*) AND (mortalit* OR death* OR fatal*) 
 
Open Access Theses and Dissertations (OATD) 
(running OR jogging OR runner* OR jogger*) AND (mortalit* OR death* OR fatal*) 
 
PubMed/MEDLINE 
(running[TW] OR jogging[TW] OR runner*[TW] OR jogger*[TW]) AND (mortalit*[TW] 
OR death*[TW] OR fatal*[TW]) 
 
Scopus 
title-abs-key(running OR jogging OR runner* OR jogger*) AND title-abs-key (mortalit* OR 
death* OR fatal*) 
 
Web of Science (including Science Citation Index Expanded - SCI-EXPANDED, Social 
Sciences Citation Index - SSCI, Arts & Humanities Citation Index - A&HCI, Conference 
Proceedings Citation Index- Science - CPCI-S, and Conference Proceedings Citation Index- 
Social Science & Humanities - CPCI-SSH) 
TS=(running OR jogging OR runner* OR jogger*) AND TS=(mortalit* OR death* OR 
fatal*) 
 
Supplementary file 2   Differences from the registered protocol 
 
The review protocol has been registered in the International Prospective Register of Systematic 
Reviews – PROSPERO (registration id: CRD42016049965). In the registered protocol, the 
search was limited to the documents published from 2013 onwards, given that a previous 
review on a similar topic was planned to be used as a reference point. However, based on a 
suggestion from a reviewer, while revising the manuscript we decided to conduct the search 
without a time limit. Furthermore, in the registered protocol the search was planned to be done 
in Academic Search Premier and MasterFILE Premier (among other databases). However, in 
the updated search we used Academic Search Ultimate and MasterFILE Complete; larger 
variants of the two bibliographic databases, because our university library in the meantime 
expanded its subscription to these larger databases, and we could not access Academic Search 
Premier and MasterFILE Premier anymore. 
Supplementary table 1   Summary of studies on the association between running participation and the risk of all-cause, cardiovascular, and cancer mortality 
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Exposure group: members 
of a nationwide runners 
club aged ≥ 50 years (n = 
451, 83% males); 
Controls: permanent 
university staff and faculty 
between 50 and 72 years 
of age recruited from the 
roster of the Stanford 
University Lipid Research 
Clinics Prevalence Study 






8 years n/a 
Exposure 
group: n = 451; 
Total number of 
runners (across 
both groups): n 
= 534 




n = 247 
Whole sample: 
38 (all-cause), 11 
(CVD); Exposure 
group: 8 (all-
cause), 1 (CVD); 
Controls: 30 (all-
cause), 10 (CVD) 
Membership 





ever run for 
exercise for a 
period of 




Baseline age, initial 




DI), educational level, 
smoking, body mass 
index, history of 








All-cause mortality: HR = 
0.23 (95% CI: 0.10, 0.56) n/a 




Exposure group: members 
of a nationwide runners 
club aged ≥ 50 years (n = 
538, 82% males); 
Controls: permanent 
university staff and faculty 
between 50 and 72 years 
of age recruited from the 
roster of the Stanford 
University Lipid Research 
Clinics Prevalence Study 






13 years 12,493 Exposure group: n = 538 
Controls: n = 
423 
Whole sample: 

















ever run for 
exercise for a 
period of 




Baseline age, sex, 
weekly time spent in 
aerobic exercise other 
than running, and 
smoking. BMI and 
alcohol consumption 
were considered but 
were not included in 
















All-cause mortality: HR = 
0.36 (95% CI: 0.20, 0.65), 
rate ratio = 3.28 (no p-
value reported); CVD 
mortality: rate ratio = 2.68 
(p = 0.55); Cancer 
mortality: rate ratio = 2.77 
(p = 0.56) 
n/a 
Chakravarty 




Exposure group: members 
of a nationwide runners 
club aged ≥ 50 years (n = 
538, 84% males); 
Controls: permanent 
university staff and faculty 
between 50 and 70 years 
of age recruited from the 
roster of the Stanford 
University Lipid Research 
Clinics Prevalence Study 






19 years 17,201 
Exposure 
group: n = 538; 
Total number of 
runners (across 
both groups): n 
= 681 




n = 280 
Whole sample: 
225 (all-cause), 
72 (CVD), 71 
(cancer); 
Exposure group: 













ever run for 
exercise for a 
period of 




Baseline age, gender, 
and initial disability 




DI). Although initially 
considered as 
covariates, BMI, 
smoking history, and 
weekly aerobic 
exercise at baseline 
"did not meet 
statistical significance 

















All-cause mortality: HR = 
0.61 (95% CI: 0.45, 0.82), 
rate ratio = 2.5 (p < 
0.001); CVD mortality: 
rate ratio = 2.1 (p = 
0.001); Cancer mortality: 
rate ratio = 1.9 (p = 0.004) 
n/a 



















Participants were 18-100 
years old adults referred 
for periodic preventive 
medical examination at a 
clinic in Dallas, Texas (n = 
55,137 for all-cause 
mortality analysis, 52,941 
for CVD mortality analysis, 
52,917 for cancer mortality 
analysis, 74% males). 
Those reporting 
myocardial infarction, 
stroke or cancer at 
baseline, and those who 
died within less than 1 
year of follow up were 























samples)   
827,055 
n = 13,016 (all-
cause mortality 
analysis); n = 
12,622 (CVD 
mortality 













































In Model 1: baseline 
age, sex, examination 




running (0, 1-499 
MET-min/wk, ≥500 
MET-min/wk), and 
parental CVD (except 
in cancer mortality 
analysis) 
 
In Model 2: baseline 
age, sex, examination 
year, smoking status, 
overweight/obesity 
based on body mass 












HR(total) = 0.70 (95% CI: 
0.64, 0.77), HR(males) = 
0.71 (95% CI: 0.64, 0.78), 
HR(females) = 0.61 (95% 
CI: 0.45, 0.85); CVD 
mortality: HR = 0.55 (95% 
CI: 0.46, 0.65), HR(males) 
= 0.56 (95% CI: 0.47, 
0.67), HR(females) = 0.32 
(95% CI: 0.16, 0.64);  
Cancer mortality: 




All-cause mortality: HR = 
0.81 (95% CI: 0.73, 0.88), 
CVD mortality: HR = 0.71 
(95% CI: 0.60, 0.85) 
In Lee et al. (2014), HRs and 
their 95% CIs for all-cause and 
CVD mortality available for 
quintiles of running time, 
running distance, weekly 
frequency, running speed, and 
total volume of running. 
 
In Lee et al. (2016a), HRs and 
their 95% CIs for all-cause and 
CVD mortality available for 
groups by running time in 
minutes/wk (0, <51, 51-80, 81-
119, 120-175, 176-209, 210-
269, and ≥270), running 
distance in miles/wk (0, <6, 6-8, 
9-12,13-19, 20-23, 24-30, ≥31), 
weekly frequency of running (0, 
1-2, 3, 4, 5, 6, ≥7), and total 
amount of running in MET-
minutes/wk (0, <506, 506-812, 
813-1199, 1200-1839, 1840-
2249, 2250-2943, ≥2944). 
These represent non-runners 
(first group), the first four 
quintiles (second to fifth group), 
and three tertiles of the last 
quintile (sixth to eight group), 
except for weekly frequency of 
running that includes 7 groups. 
 
In Lee et al. (2016b), HRs and 
their 95% CIs for cancer 
mortality available for quintiles 
of running time, running 
distance, weekly frequency, 
and total volume of running. 
 
The results are summarised in 























Participants were 18-85 
years old adults who 
participated in NHANES 
1999-2006 surveys (n = 
16,049, 49% males). 
Those with self-reported 
physician-diagnosed 
congestive heart failure, 
coronary artery disease, 
heart attack, stroke, 
emphysema, or bronchitis 









follow-up)   n/a 
n = 358 (≥2000 
MET-min/month 




n = 15,691 
(<2000 MET-
min/month of 






































Baseline age, gender, 
race-ethnicity, body 









min/month for the 
following activities: 
aerobics; basketball; 
bicycling; dance; stair 
climbing; swimming; 






≥2000 MET-min/month of 
jogging and ≥2000 MET-
min/month of running 
were not significantly 
associated with the risk of 
all-cause mortality (results 
not shown in the paper) 
n/a 
 














































Participants were 30-98 
years old adults from the 
population-representative 
Health Survey from 
England and Scottish 
Health Survey (n = 80,306 
for all-cause mortality 
analysis and 75,014 for 
CVD mortality analysis, 
46% males). Those 
reporting doctor-diagnosed 
CVD at baseline were 
excluded from the 
analyses on CVD 
mortality. In a sensitivity 
analysis participants who 
died in the first 24 months 
of follow-up were 
excluded. 
 
In a subsequent sensitivity 
analysis, Stamatakis et al. 
(2017), due to missing 
income data, 35% of the 
full sample was excluded 
(n = 52,031 for the all-
cause mortality analysis 
and n = 48,965 for the 





















n = 4,012 (all-
cause mortality 








analysis: n = 
2857 (all-cause 
mortality 






































analysis - Whole 
sample: data not 
shown; Runners: 
36 (all-cause), 5 
(CVD); Non-





























BMI, smoking status, 
education level, 
doctor-diagnosed 
cancer, and weekly 
volume of other 
physical activity in 
MET-hours/week. The 
all-cause mortality 






In the subsequent 
sensitivity analyses 
additionally adjusted 
for occupational social 







HR(total) = 0.87 (95% CI: 
0.68, 1.11); CVD 
mortality: HR = 0.81 (95% 
CI: 0.47, 1.39); Cancer 
mortality: HR = 0.65 (95% 
CI: 0.43, 0.97) 
 
In the subsequent 
sensitivity analysis - 
HR(total) = 1.06 (95% CI: 
0.76, 1.48); CVD 
mortality: HR = 0.84 (95% 
CI: 0.34, 2.04). 
 
 
HRs and their 95% CIs for all-
cause and CVD mortality are 
available for intensity ('Lower', 
'Higher'), weekly duration 
('Low', 'High'), and weekly 
volume ('Low', 'High') 
categories. Low and high 
intensity, respectively, were 
defined as answering "no" or 
"yes" to the question:  "Was the 
effort of [(name of activity] ) 
usually enough to make you out 
of breath or sweaty?". Low/high 
weekly duration and volume 
were defined using median 
split. Additional results for more 
detailed categorisations of 
running doses were obtained 
upon request from the authors. 
 
The results are summarised in 
Supplementary table 2. 
 


















Participants were 20-79 
years old adults randomly 
selected from the 
Copenhagen Population 
Register (n = 4,658), who 
attended two examinations 
(1976-1978 and 1981-
1983). Those with a 
history of myocardial 
infarction were excluded 
from the original sample. 
n/a 17-22 years (range) n/a 
Runners in at 
least one 
survey year n = 




runners”) n = 96   
Non-runners 
in at least 
one survey 



































plasma high density 
lipoprotein cholesterol, 






with the risk of all-cause 
mortality only found for 
“persistent runners”: HR = 
0.39 (95% CI: 0.19, 0.73) 
n/a 




Participants were 20-98 
years old adults randomly 
selected from the 
Copenhagen Population 
Register (n = 18,219; 47% 
males). Those with a 
history of coronary heart 
disease, stroke, and/or 
cancer were excluded 




















Males n = 
1,089; Females 




Males n = 
1,098; Females 







Males n = 
7,398 and 





Males n = 
7,501 and 











Males n = 4,934 





n = 91 and 





n = 4,843 and 
females n = 


































time physical activity, 
resting heart rate, 
cholesterol, body 
mass index, systolic 
blood pressure, and 









HR(males) = 0.78 (95% 
CI: 0.64, 0.94), 
HR(females) = 0.71 (95% 
CI: 0.50, 1.01); Coronary 
heart disease mortality: 
HR(males) = 0.32 (95% 
CI: 0.15, 0.67), 
HR(females) = 0.48 (95% 
CI: 0.12, 1.96); Stroke 
mortality: HR(males) = 
0.95 (95% CI: 0.42, 2.18), 
HR(females) = 0.85 (95% 
CI: 0.21, 3.42); Cancer 
mortality: HR(males) = 
0.82 (95% CI: 0.58, 1.16), 
HR(females) = 0.68 (95% 
CI: 0.38, 1.23)  
HRs and their 95% CIs for all-
cause mortality are available for 
groups by weekly duration, 
weekly frequency, and pace of 
running. The analysis included 
participants who participated in 
the second, third, and fourth 
surveys. 




Participants were 20-92 
years old adults randomly 
selected from the 
Copenhagen Population 
Register who participated 
in the fourth examination, 
2001-2003 (n = 1,511; 
51% males). Those with a 
history of coronary heart 
disease, stroke, and/or 
cancer were excluded 











12 years n/a n = 1,098 




Whole sample: n 
= 128; Sample of 
runners n = 28; 
Sample of 
"sedentary" non-













Baseline age, sex, 
smoking, alcohol 






No results are available 
for the association 
between overall running 
participation and mortality. 
The results from dose-
response analyses are 
summarised in 
Supplementary table 2. 
HRs and their 95% CIs for all-
cause mortality are available for 
groups by weekly duration of 
running (<1 hour, 1-2.4 hours, 
2.5-4 hours, >4 hours), weekly 
frequency of running (≤1 time, 
2-3 times, >3 times), running 
pace (slow, average, fast) and 
overall "dose" of running (light 
jogger, moderate jogger, 
strenuous jogger). "Sedentary" 
non-runners (not all non-
runners) were used as the 
reference group. 
 
The results are summarised in 
Supplementary table 2. 




Participants were 20+ 
years old adults randomly 
selected from the 
Copenhagen Population 
Register who participated 
in the third examination, 
1991-1994 (n = 1,325; 
51% males). Those with a 
history of coronary heart 
disease, stroke, cancer, 
and/or missing information 
about leisure-time physical 
activity were excluded 







25 years n/a n = 309 




Whole sample: n 
= 693; Sample of 
runners n = 64; 
Sample of 
"sedentary" non-








Baseline age, sex, 











All-cause mortality: HR = 
0.72 (95% CI: 0.55, 0.94); n/a 













Wang et al. 
(2013), China 
(Shanghai) 
Participants were 40-74 
years old men recruited 
from 2002-2006 from 
urban communities in 
Shanghai, China (n = 
61,477). Those with 
previously diagnosed 
cancer were excluded 
from the analyses. A 
sensitivity analysis was 
performed on participants 
without a history of CVD at 
baseline and who did not 
die within the first year of 







(mean) 336,894 3,214 58,263 
Whole sample: 
2,421 (all-cause), 











In the sensitivity 















in jogging or 
running for 
exercise in 































alcohol intake, daily 
physical activity other 
than exercise, 
participation in 
exercise other than 
jogging, body mass 
index, history of CVD, 




total energy intake, 
intake of red meat, 
intake of vegetables 





All-cause mortality: HR = 
0.73 (95% CI: 0.59, 0.90); 
CVD mortality: HR = 0.74 
(95% CI: 0.52, 1.06); 
Cancer mortality: HR = 
0.69 (95% CI: 0.51, 0.94). 
 
In the sensitivity analysis - 
All-cause mortality: HR = 
0.79 (95% CI: 0.63, 0.99); 
CVD mortality: HR = 0.90 
(95% CI: 0.60, 1.36); 
Cancer mortality: HR = 
0.74 (95% CI: 0.54, 1.02) 
n/a 
 
   Lee et al (2016a) = reference number 30; Lee et al (2016b) = reference number 50 
Supplementary table 2   Summary results of the studies on the dose-response relationship between running and the risk of all-cause mortality 
Dose type Lee et al. (2014; pace), Lee et al. (2016; other variables) Schnohr et al. (2015) Oja et al. (2017) Category HR (95% CI) Category HR (95% CI) Category HR (95% CI) 
Duration 
<51 min/week 0.70 (0.58, 0.85) < 1 hour/week 0.47 (0.29, 0.77) <51 min/week 0.93 (0.67, 1.28) 
51-80 min/week 0.67 (0.55, 0.80) 
1-2.4 hours/week 0.29 (0.11, 0.80) 
51-80 min/week 0.75 (0.39, 1.44) 
81-119 min/week 0.67 (0.55, 0.82) 81-119 min/week 0.58 (0.22, 1.55) 
120-175 min/week 0.71 (0.58, 0.86) 120-175 min/week 1.18 (0.61, 2.28) 
176-209 min/week 0.74 (0.52, 1.04) 
2.5-4 hours/week 0.65 (0.20, 2.07) 
176-209 min/week 0.75 (0.19, 3.02) 
210-269 min/week 0.58 (0.40, 0.83) 210-269 min/week 0.38 (0.05, 2.73) 
 ≥270 min/week 0.97 (0.73, 1.27) > 4 hours/week 0.60 (0.08, 4.36)  ≥270 min/week 0.92 (0.38, 2.21) 
Frequency 
1-2 times per week 0.65 (0.51, 0.84) ≤1 time 0.29 (0.12, 0.72) ≤1 time per week 1.05 (0.77, 1.42) 
2-3 times 0.32 (0.15, 0.69) 2 times per week 0.62 (0.31, 1.25) 
3 times per week 0.68 (0.56, 0.82) 3 times per week 0.69 (0.29, 1.65) 
4 times per week 0.67 (0.56, 0.80) 
>3 times  0.71 (0.29, 1.75) 
4 times per week 1.05 (0.39, 2.81) 
5 times per week 0.71 (0.60, 0.84) 5 times per week 0.30 (0.04, 2.12) 
6 times per week 0.73 (0.57, 0.93) 6 times per week 0.41 (0.06, 2.92) 
7+ times per week 0.87 (0.65, 1.15) 7+ times per week 1.93 (0.92, 4.05) 
Pace/speed 
<6 mph 0.81 (0.66, 0.97) Slow (<6 mph) 0.51 (0.24, 1.10) Lower perceived intensity (<6 mph) 1.02 (0.59, 1.78) 
6-6.6 mph 0.71 (0.56, 0.87) 
Average (6-7 mph) 0.38 (0.22, 0.66) 
Higher perceived intensity 
(≥6 mph) 0.84 (0.64, 1.10) 
6.7-7 mph 0.67 (0.47, 0.87) 
7.1-7.5 mph 0.63 (0.46, 0.80) Fast (>7 mph) 0.94 (0.40, 2.18) 
≥7.6 mph 0.65 (0.43, 0.88) 
Total volume 
<506 MET-min/week 0.67 (0.55, 0.81) 
"Light" runners, <1800 MET-
min/week 0.22 (0.10, 0.47) 
<506 MET-min/week 0.93 (0.68, 1.28) 
506-812 MET-min/week 0.71 (0.59, 0.85) 506-812 MET-min/week 0.61 (0.32, 1.17) 
813-1199 MET-min/week 0.72 (0.60, 0.87) 813-1199 MET-min/week 0.82 (0.34, 1.98) 
1200-1839 MET-min/week 0.66 (0.54, 0.80) 1200-1839 MET-min/week 1.14 (0.57, 2.28) 
1840-2249 MET-min/week 0.70 (0.49, 0.99) "Moderate" runners, 1800 - 
2880 MET-min/week 0.66 (0.32, 1.38) 
1840-2249 MET-min/week 0.40 (0.06, 2.83) 
2250-2943 MET-min/week 0.67 (0.46, 0.96) 2250-2943 MET-min/week 0.60 (0.08, 4.23) 
 ≥2944 MET-min/week 0.88 (0.65, 1.19) "Strenuous" runners, >2880 MET-min/week 1.97 (0.48, 8.14)  ≥2944 MET-min/week 1.24 (0.46, 3.30) 
 
Lee et al (2016) = reference number 30 
Supplementary table 3   Methodological quality appraisal using the Newcastle-Ottawa Quality Assessment Scale (NOS) for cohort studies 
Study 
Representativeness 








outcome of interest 
was not present at 
start of study 
Comparability of 
cohorts on the 













Fries et al. (1994); Wang et al. 
(2002); Chakravarty et al. (2008) - - - - ** * * - 4 
Lee et al. (2014, 2016a, 2016b) * * - * ** * * - 7 
Loprinzi (2015) * * * * ** * * * 9 
Oja et al. (2017); 
Stamatakis et al. (2017) * * * * ** * * * 9 
Schnohr et al. (2000, 2013, 2015, 
2018) * * - * ** * * * 8 
Wang et al. (2013) * * * * ** * * * 9 
 
 “-” =criteria not met; “*”=one point for meeting criteria; “**”=two points for meeting criteria; Overall score: 0-3 points = “poor quality”; 4-6 points = “fair quality”; 7-9 points = “good quality” 
Lee et al (2016a) = reference number 30; Lee et al (2016b) = reference number 50 
 
 
Supplementary table 4   Association between the dose or running and the risk of all-cause 
mortality: meta-regression estimates for the linear trend 
Type of dose β0 (95% CI) β1 (95% CI) p 
Weekly frequency (days) 0.56 (0.36, 0.76) 0.03 (-0.02, 0.08) 0.202 
Weekly duration (minutes) 0.66 (0.52, 0.80) 0.00 (0.00, 0.00) 0.923 
Pace (mph) 1.03 (0.13, 1.93) -0.05 (-0.19, 0.08) 0.448 
Total volume (MET-minutes/week) 0.64 (0.44, 0.84) 0.00 (0.00, 0.00)* 0.634 
 
β0=intercept; 95% CI=95 percent confidence interval; β1=unstandardised regression coefficient; p=p-
value for the linear trend; *Given that MET-minutes/week is a very small unit size to express the total 
volume of running, the following, precise β1 (95% CI) should be used to calculate the estimated pooled 
HR: 5.57e-05 (95% CI: -6.50e-05, 1.77e-04) 
Supplementary figure 1   Running participation and all-cause mortality risk: a sensitivity 
meta-analysis of hazard ratios including only the studies classified as being of “good quality” 
Study quality was assessed using the Newcastle-Ottawa Quality Assessment Scale for cohort studies, 
with the overall score of 7-9 points being classified as “good quality”; HR=adjusted hazard ratio (the 
list of variables that were adjusted for in each study is available in online supplementary table 1); 95% 
CI=95% confidence interval for HR; RE Model=pooled effect size from a random-effects meta-analysis 
model; p-value for the pooled HR <0.001; Heterogeneity I2 = 18.07% (p = 0.453) 
Supplementary figure 2   Running participation and all-cause mortality risk: a sensitivity 
meta-analysis including the most recent study from the Copenhagen City Heart Study cohort 
Schnohr et al. (2018) included only participants who participated in the third examination (1991-1994), 
which resulted in a shorter follow-up, a lower sample size, and a lower number of deaths when 
compared to a previous study from the same cohort; HR=adjusted hazard ratio (the list of variables that 
were adjusted for in each study is available in online supplementary table 1); 95% CI=95% confidence 
interval for HR; RE Model=pooled effect size from a random-effects meta-analysis model; p-value for 
the pooled HR <0.001; Heterogeneity I2 = 5.13% (p = 0.346) 
Supplementary figure 3   Running participation and all-cause mortality risk: a sensitivity 
meta-analysis including HRs from an alternative model in Lee et al. (2014) study 
 
A description of the model from the Lee et al. (2014) study can be found in online supplementary table 
1 (Model 2); HR=adjusted hazard ratio (the list of variables that were adjusted for in each study is 
available in online supplementary table 1); 95% CI=95% confidence interval for HR; RE Model=pooled 
effect size from a random-effects meta-analysis model; p-value for the pooled HR <0.001; 
Heterogeneity I2 < 0.001% (p = 0.550) 
 
Supplementary figure 4   Running participation and all-cause mortality risk: a sensitivity 
meta-analysis including HRs from an alternative model in Lee et al. (2014) study and from 
Stamatakis et al. (2017) study 
 
A description of the model from the Lee et al. (2014) study can be found in online supplementary table 
1 (Model 2); HR=adjusted hazard ratio (the list of variables that were adjusted for in each study is 
available in online supplementary table 1); 95% CI=95% confidence interval for HR; RE Model=pooled 
effect size from a random-effects meta-analysis model; p-value for the pooled HR <0.001; 
Heterogeneity I2 = 0.01% (p = 0.271) 
 
Supplementary figure 5   Running participation and all-cause mortality risk among females: 
a meta-analysis of hazard ratios 
HR=adjusted hazard ratio (the list of variables that were adjusted for in each study is available in online 
supplementary table 1); 95% CI=95% confidence interval for HR; RE Model=pooled effect size from 
a random-effects meta-analysis model; p-value for the pooled HR <0.001; Heterogeneity I2 < 0.001% 
(p = 0.553) 
Supplementary figure 6   Running participation and all-cause mortality risk among males: a 
meta-analysis of hazard ratios 
HR=adjusted hazard ratio (the list of variables that were adjusted for in each study is available in online 
supplementary table 1); 95% CI=95% confidence interval for HR; RE Model=pooled effect size from 
a random-effects meta-analysis model; p-value for the pooled HR <0.001; Heterogeneity I2 < 0.001% 
(p = 0.547) 
Supplementary figure 7   Running participation and cardiovascular mortality risk: a 
sensitivity meta-analysis including HRs from an alternative model in Lee et al. (2014) study 
 
A description of the model from the Lee et al. (2014) study can be found in online supplementary table 
1 (Model 2); HR=adjusted hazard ratio (the list of variables that were adjusted for in each study is 
available in online supplementary table 1); 95% CI=95% confidence interval for HR; RE Model=pooled 
effect size from a random-effects meta-analysis model; p-value for the pooled HR <0.001; 
Heterogeneity I2 < 0.001% (p = 0.546) 
 
Supplementary figure 8   Running participation and cardiovascular mortality risk: a 
sensitivity meta-analysis including HRs from an alternative model in Lee et al. (2014) study 
and from Stamatakis et al. (2017) study 
 
A description of the model from the Lee et al. (2014) study can be found in online supplementary table 
1 (Model 2); HR=adjusted hazard ratio (the list of variables that were adjusted for in each study is 
available in online supplementary table 1); 95% CI=95% confidence interval for HR; RE Model=pooled 
effect size from a random-effects meta-analysis model; p-value for the pooled HR <0.001; 
Heterogeneity I2 = 0.43% (p = 0.554) 
 
Supplementary figure 9   A possible alternative directed acyclic graph for the relationship 
between running participation and mortality risk 
 
Green circle = exposure; blue circle = outcome; light grey circle = unobserved variable; dark grey circle 
= other variable; arrow = the direction of the causal relationship 
 
